

d) adding a test compound to said hollow fiber bioreactor, and determining the effects of said test compound on the lytic organism.

30. A hollow fiber bioreactor comprising: multiple hollow fibers arranged to form an extracapillary space (ECS); a stable cell line growing in said ECS at a density of at least 10^6 cells per milliliter; and a lytic organism of a type capable of infecting and lysing cells of said stable cell line.


Q2
corr

31. A method according to claim 30 where said stable cell line is selected from mammalian cell lines, insect cell lines, yeast cell lines and bacterial cell lines.

REMARKS

Currently claims 15-31 are pending. Claims 1-14 have been canceled. The claims have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependency. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Frank P. Grassler

Attorney for Applicants

Registration No. 31,164

Date: 12/11/01

GlaxoSmithKline Inc.

Corporate Intellectual Property

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Phone: 919-483-2482

Facsimile: 919-483-7988